Skip Navigation LinksHome   >   Research & Development   >   OCT461201


OCT461201 is a highly selective and potent CB2 agonist. The CB2 receptor is a target for a range of neuroinflammatory, inflammatory, fibrotic and autoimmune diseases and conditions. OCT461201 has undergone extensive in vitro and in vivo testing, including efficacy testing in disease models. The compound does not interact with CB1, the receptor responsible for the psychotropic effects of THC. 

OCT461201 has been successfully evaluated in two different disease models and OCT believes the compound has the potential to be an effective treatment for IBS, a chronic intestinal disorder highly associated with visceral pain, altered bowel motility resulting in either diarrhoea or constipation, and an increase in visceral hypersensitivity. OCT is initially developing OCT461201 for this indication, with later indications in IBD and Neuropathic Pain. 

As OCT461201 continues pre-clinical development, work includes studies on drug metabolism and pharmacokinetics (DMPK), safety pharmacology and toxicology. Production of OCT461201 is under good manufacturing practices (GMP).